A Phase I, Open-Label, Multi-centre Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of AZD8330 in Patients With Advanced Malignancies
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess safety and tolerability of AZD8330 in patient with advanced malignancies.
Emerging Oncology Medical Science Director, MD
United States: Food and Drug Administration
|Research Site||Allentown, Pennsylvania|
|Research Site||Abilene, Texas|